Neoadjuvant tedavi sonrası küçük hücreli dışı akciğer kanseri olan hastaların cerrahi sonuçları

Abstract

Objective: Although, anatomical resection of non-small celllung cancer (NSCLC) following neoadjuvant therapy is stillcontroversial, it is a widely accepted approach for thoracic surgerypractice. The aim of this study is to briefly evaluate clinical results,long term survival, and factors affecting survival of the patientswith locally advanced NSCLC, pancoast tumour and lung cancerwith solitary brain metastasis, who have been operated at ourinstitution following neoadjuvant therapy.Materials and Method: Between March 2006 and March2012, 70 patients with NSCLC diagnosis who underwent anatomicpulmonary resection following neoadjuvant therapy were includedin the study.Results: A three year survival (39%) and a 5-year survival(29%) were 16±6.8 and 37±9.89 months, respectively. The meansurvival was found to be 37.15±3.06 months. When survival ratewas evaluated according to localization of tumor, it was lower incentral and left upper lobe tumors compared to other anatomicallocalizations (P=0.042). The mean 5-year survival times were50.00±5.65 months in stage 0 patients, 35.39±5.85 months in stage1 patients, 37.40±6.89 months in stage 2 patients and 21.44±3.10months in stage 3 patients.Conclusion: We can achieve significant survival results by theanatomical pulmonary resection following neoadjuvant therapy.